Last Updated: 2026-03-21
TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis and autophagy, playing a critical role in cellular clearance mechanisms. TFEB belongs to the MITF (Microphthalmia-associated transcription factor) family of basic helix-loop-helix leucine zipper transcription factors[1]. When activated, TFEB translocates to the nucleus and coordinates the expression of genes involved in lysosome formation, autophagy, and lipid metabolism. This mechanism is particularly relevant to neurodegenerative diseases, where impaired lysosomal function contributes to protein aggregate accumulation[2].
The TFEB-mediated lysosomal biogenesis pathway represents a fundamental cellular defense mechanism against proteostatic stress. By upregulating the lysosomal-autophagic machinery, cells can clear misfolded proteins, damaged organelles, and other cellular debris that accumulate during aging and disease[3]. This page provides a comprehensive overview of TFEB signaling, its dysregulation in neurodegenerative diseases, and therapeutic strategies targeting this pathway.
TFEB is a 476-amino acid transcription factor encoded by the TFEB gene located on chromosome 6p21[4]. The protein contains several key structural domains:
TFEB binds to the CLEAR (Coordinated Lysosomal Expression and Regulation) element, a palindromic 10-base pair sequence (GTCACGTGAC) found in the promoters of lysosomal genes[5]. This sequence was first identified in cathepsin genes and is now recognized as the master regulatory sequence controlled by TFEB.
TFEB regulates a network of approximately 400-500 genes collectively known as the lysosomal-autophagic network[6]. Key target categories include:
Lysosomal Proteins:
Autophagy Machinery:
Lipid Metabolism:
The mechanistic target of rapamycin complex 1 (mTORC1) is the primary regulator of TFEB activity[7]. Under nutrient-rich conditions:
Upon nutrient starvation or lysosomal stress:
TFEB can also be regulated through mTORC1-independent mechanisms[8]:
TFEB undergoes multiple post-translational modifications:
| Modification | Site | Effect |
|---|---|---|
| Phosphorylation | Ser142, Ser211 | Cytoplasmic retention |
| Phosphorylation | Ser3 | Nuclear export |
| Acetylation | Lysine residues | Transcriptional activity |
| Sumoylation | Lys275 | Protein stability |
| Ubiquitination | Multiple sites | Degradation |
In Alzheimer's disease (AD), TFEB activity is generally reduced, contributing to impaired lysosomal function and amyloid-beta accumulation[9]:
Amyloid Processing:
Tau Pathology:
Therapeutic Implications:
Parkinson's disease (PD) is characterized by alpha-synuclein aggregation and dopaminergic neuron loss. TFEB dysfunction contributes to these pathologies[11]:
Alpha-Synuclein Clearance:
Mitochondrial Quality Control:
Dopaminergic Neuron Vulnerability:
Huntington's disease (HD) involves mutant huntingtin (mHTT) protein aggregation. TFEB plays a protective role[12]:
ALS involves TDP-43 proteinopathy and motor neuron degeneration[13]:
Several compounds can activate TFEB[14]:
Direct TFEB Activators:
Indirect Activators (via mTOR inhibition):
Natural Compounds:
TFEB Overexpression:
CRISPR Activation:
Fasting and Calorie Restriction:
Exercise:
TFEB in microglia is particularly relevant to neuroinflammation[16]:
Astrocytic TFEB has emerging roles:
TFEB in oligodendrocytes:
TFEB represents a key messenger in lysosome-to-nucleus signaling[17]:
TFEB integrates signals from multiple organelles:
TFEB shows circadian regulation:
TFEB activity declines with age[18]:
Anti-aging strategies targeting TFEB:
Several approaches are in development[19]:
| Agent | Mechanism | Stage | Indication |
|---|---|---|---|
| Rapamycin | mTOR inhibitor | Phase 2-3 | AD, PD |
| Metformin | AMPK activator | Phase 2-3 | AD |
| KHS-101 | Direct TFEB activator | Preclinical | PD |
| Trehalose | TFEB activator | Phase 2 | HD |
Settembre et al. 'TFEB: a master regulator of lysosomal biogenesis'. Nature Reviews Molecular Cell Biology. 2013. ↩︎
Decressac et al. TFEB overexpression and neuroprotection in PD. Proceedings of the National Academy of Sciences. 2013. ↩︎
Ballabio and Gieselmann, Lysosomal disorders. Nature Reviews Disease Primers. 2019. ↩︎
Hemesath et al. Microphthalmia, a critical factor in pigment cell development. Nature. 1994. ↩︎
Sardiello et al. A gene network regulating lysosomal biogenesis. Science. 2009. ↩︎
Settembre et al. TFEB controls cellular lipid metabolism. EMBO Journal. 2013. ↩︎
'Raben and Puertollano, TFEB and TFE3: lysosomal-autophagic master regulators'. Journal of Molecular Biology. 2016. ↩︎
Medina et al. TFEB is activated by nutrient stress. EMBO Reports. 2011. ↩︎
Wang et al. TFEB and autophagy in Alzheimer's disease. Molecular Neurodegeneration. 2016. ↩︎
Zhang et al. TFEB activators for AD treatment. Nature Reviews Drug Discovery. 2022. ↩︎
Decressac and Bjorklund, TFEB in Parkinson's disease. Neurobiology of Disease. 2017. ↩︎
Perea et al. TFEB and Huntington's disease. Human Molecular Genetics. 2018. ↩︎
Chua et al. TFEB in ALS pathogenesis. Acta Neuropathologica. 2019. ↩︎
Johnson et al. Small molecule TFEB activators. Journal of Medicinal Chemistry. 2021. ↩︎
Kwon et al. KHS-101 as TFEB activator. International Journal of Molecular Sciences. 2026. ↩︎
Sanchez-Mejias et al. TFEB in microglia. Glia. 2020. ↩︎
Roca-Agujetas et al. Lysosome-nucleus signaling via TFEB. Cellular and Molecular Life Sciences. 2019. ↩︎
Kouroku et al. TFEB and aging. Autophagy. 2008. ↩︎
Liu et al. Clinical development of TFEB-targeted therapies. Nature Reviews Neurology. 2023. ↩︎